| |
| Please Note - Streaming News is only available to subscribers to the Active Level and above |
|
|
|
Avacta files clinical trial application for cancer drug candidate
StockMarketWire.com
|
Cancer therapies and diagnostics group Avacta said it had submitted a clinical trial application in the UK for a phase 1 dose-escalation and expansion study of its lead drug candidate to treat patients with locally advanced or metastatic selected solid tumours.
The dose-escalation phase of the study would be carried out in 15-to-20 patients, and was designed to evaluate the safety of AVA6000 in humans and establish the appropriate dosing levels.
'If the AVA6000 study shows that the pre|CISION chemistry is effective in reducing systemic toxicity of Doxorubicin in humans, then it can be applied to a range of other established chemotherapies to improve their safety and efficacy,' the company said.
At 8:05am: (LON:AVCT) Avacta Group PLC share price was 0p at 111.5p
Story provided by StockMarketWire.com
|
|
|
|
|
|
